{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T22:18:11Z","timestamp":1788214691395,"version":"build-2803163510"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["RGPIN: 03830-2014 and 2020-05066"],"award-info":[{"award-number":["RGPIN: 03830-2014 and 2020-05066"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001805","name":"Canada Foundation for Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001805","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Chem."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Alzheimer\u2019s disease (AD) is characterized by the aggregation of amyloid-beta (A\u03b2) peptides, particularly A\u03b242 and A\u03b240, which contribute to neurotoxicity and disease progression. The development of novel small molecule inhibitors capable of preventing A\u03b2 aggregation represents a promising therapeutic strategy. We report the design, synthesis and evaluation of a novel class of 1,4-diazepanes as anti-amyloid agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A novel series of (1,4-diazepan-1-yl) (phenyl)methanone derivatives (\n                      <jats:bold>4a\u2013n<\/jats:bold>\n                      ) incorporating a flexible seven-membered 1,4-diazepane scaffold was synthesized and screened for inhibition of A\u03b242 and A\u03b240 aggregation using a fluorescence-based thioflavin-T (ThT) kinetic assay. The effects of lead compounds on A\u03b2 fibril morphology were subsequently examined by transmission electron microscopy (TEM). Neuroprotective potential was assessed by determining the ability of selected compounds to attenuate A\u03b242-induced cytotoxicity in mouse hippocampal HT22 cells. Antioxidant activity was investigated using both the 2,2\u2019-diphenyl-1-picryl-hydrazyl (DPPH) radical scavenging assay and hydrogen peroxide-induced oxidative stress models in HT22 cells. Blood\u2013brain barrier permeability was evaluated using the parallel artificial membrane permeability assay (PAMPA-BBB). In addition, molecular docking studies were performed using Discovery Studio Structure-Based Design software using A\u03b2 aggregates to characterize ligand\u2013A\u03b2 interactions and provide mechanistic insights into the observed anti-aggregation activity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the synthesized derivatives, compound\n                      <jats:bold>4m<\/jats:bold>\n                      emerged as the lead A\u03b242 aggregation inhibitor, demonstrating 42.0% inhibition at 25\u00a0\u00b5M. Notably, compounds\n                      <jats:bold>4k<\/jats:bold>\n                      and\n                      <jats:bold>4l<\/jats:bold>\n                      demonstrated dual inhibitory activity toward both A\u03b242 and A\u03b240 aggregation, with inhibition values of 40.4% and 57.3% for\n                      <jats:bold>4k<\/jats:bold>\n                      , and 36.1% and 59.2% for\n                      <jats:bold>4l<\/jats:bold>\n                      , respectively, at 25\u00a0\u00b5M. Compounds\n                      <jats:bold>4k\u2013m<\/jats:bold>\n                      significantly reduced A\u03b242-induced cytotoxicity in mouse hippocampal HT22 cells. In addition, compound\n                      <jats:bold>4l<\/jats:bold>\n                      exhibited antioxidant activity and attenuated hydrogen peroxide-induced cytotoxicity. Computational analyses suggested that these 1,4-diazepane derivatives interact with both the N- and C-termini regions of A\u03b242 and A\u03b240, stabilizing peptide assemblies and hindering further aggregation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      These findings identify the 1,4-diazepane ring as a novel structural scaffold for the development of anti-amyloid agents. The dual inhibition of A\u03b242 and A\u03b240 aggregation, combined with neuroprotective and antioxidant effects, highlights compounds\n                      <jats:bold>4k\u2013m<\/jats:bold>\n                      as attractive lead candidates for further optimization toward therapeutic intervention in Alzheimer\u2019s disease.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fchem.2026.1919936","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T22:10:23Z","timestamp":1788214223000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel 1,4-Diazepane derivatives as amyloid-beta (A\u03b2) aggregation inhibitors"],"prefix":"10.3389","volume":"14","author":[{"given":"Rahul C.","family":"Karuturi","sequence":"first","affiliation":[{"name":"School of Pharmacy, Health Sciences Campus, University of Waterloo","place":["Waterloo, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.","family":"Hefny","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Health Sciences Campus, University of Waterloo","place":["Waterloo, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Shakeri","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Health Sciences Campus, University of Waterloo","place":["Waterloo, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen P. N.","family":"Rao","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Health Sciences Campus, University of Waterloo","place":["Waterloo, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"8863","DOI":"10.1021\/jo701558y","article-title":"Kinetics of amide formation through carbodiimide\/N-hydroxybenzotriazole (HOBt) couplings","volume":"72","author":"Chan","year":"2007","journal-title":"J. Org. Chem."},{"key":"B2","doi-asserted-by":"publisher","first-page":"9663","DOI":"10.1021\/jacs.6b05129","article-title":"Atomic resolution structure of monomorphic A\u03b242 amyloid fibrils","volume":"138","author":"Colvin","year":"2016","journal-title":"J. Am. Chem. Soc."},{"key":"B3","doi-asserted-by":"publisher","first-page":"7337","DOI":"10.1016\/j.cell.2025.11.033","article-title":"The evolving landscape of Alzheimer\u2019s disease therapy: from A\u03b2 to tau","volume":"188","author":"Courade","year":"2025","journal-title":"Cell."},{"key":"B4","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s40265-023-01858-9","article-title":"Anti-amyloid monoclonal antibodies are transformative treatments that redefine Alzheimer\u2019s disease therapeutics","volume":"83","author":"Cummings","year":"2023","journal-title":"Drugs"},{"key":"B5","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1021\/jo01158a020","article-title":"The use of sodium hydride in the alkylation of n-substituted amides","volume":"14","author":"Fones","year":"1949","journal-title":"J. Org. Chem."},{"key":"B7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","article-title":"Cerebral amyloid angiopathy and alzheimer disease","volume":"16","author":"Greenberg","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/jnc.12202","article-title":"Alzheimer\u2019s A\u03b242 and A\u03b240 peptides form interlaced amyloid fibrils","volume":"126","author":"Gu","year":"2013","journal-title":"J. Neurochem."},{"key":"B9","doi-asserted-by":"publisher","first-page":"100075","DOI":"10.1016\/j.ejmcr.2022.100075","article-title":"Design, synthesis and structure-activity relationship studies of 3-phenylpyrazino[1,2-a]indol-1(2H)-ones as amyloid aggregation and cholinesterase inhibitors with antioxidant activity","volume":"6","author":"Gujral","year":"2022","journal-title":"Eur. J. Med. Chem. Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3390\/pr9010064","article-title":"LC-UV and UPLC-MS\/MS methods for analytical study on degradation of three antihistaminic drugs, ketotifen, epinastine and emedastine: percentage degradation, degradation kinetics and degradation pathways at different pH","volume":"9","author":"Gumieniczek","year":"2021","journal-title":"Processes"},{"key":"B11","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1021\/acsmedchemlett.4c00600","article-title":"Novel phenoselenazines as amyloid-\u03b2 aggregation inhibitors","volume":"16","author":"Hefny","year":"2025","journal-title":"ACS Med. Chem. Lett."},{"key":"B12","doi-asserted-by":"publisher","first-page":"101259","DOI":"10.1016\/j.jbc.2021.101259","article-title":"Human cerebral vascular amyloid contains both antiparallel and parallel in-register A\u03b240 fibrils","volume":"297","author":"Irizarry","year":"2021","journal-title":"J. Biol. Chem."},{"key":"B13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/j.1745-7254.2008.00752.x","article-title":"Multipotent natural agents to combat Alzheimer\u2019s disease. Functional spectrum and structural features","volume":"29","author":"Ji","year":"2008","journal-title":"Acta Pharmacol. Sin."},{"key":"B14","doi-asserted-by":"publisher","first-page":"102481","DOI":"10.1016\/j.arr.2024.102481","article-title":"Pathogenesis, diagnostics, and therapeutics for Alzheimer\u2019s disease: breaking the memory barrier","volume":"101","author":"Kamatham","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","article-title":"The amyloid hypothesis in alzheimer disease: new insights from new therapeutics","volume":"21","author":"Karran","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"B16","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00044-025-03512-3","article-title":"Synthesis and evaluation of symmetric (1,4-diazepane-1,4-diyl)bis(phenylmethanone) derivatives as amyloid-beta aggregation inhibitors","volume":"35","author":"Karuturi","year":"2026","journal-title":"Med. Chem. Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40035-025-00465-w","article-title":"Second-generation anti-amyloid monoclonal antibodies for Alzheimer\u2019s disease: current landscape and future perspectives","volume":"14","author":"Kim","year":"2025","journal-title":"Transl. Neurodegener."},{"key":"B18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/antiox8010013","article-title":"Comparative analysis of antioxidant and anti-amyloidogenic properties of various polyphenol rich phytoceutical extracts","volume":"8","author":"Kleinrichert","year":"2019","journal-title":"Antioxidants"},{"key":"B19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41572-021-00269-y","article-title":"Alzheimer disease","volume":"7","author":"Knopman","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.3390\/molecules21091243","article-title":"Curcumin and resveratrol in the management of cognitive disorders: what is the clinical evidence?","volume":"21","author":"Mazzanti","year":"2016","journal-title":"Molecules"},{"key":"B21","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1021\/acsmedchemlett.6b00039","article-title":"Structure-activity relationship studies of isomeric 2,4-diaminoquinazolines on \u03b2-amyloid aggregation kinetics","volume":"7","author":"Mohamed","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1021\/acs.jmedchem.6b00975","article-title":"The essential medicinal chemistry of curcumin","volume":"60","author":"Nelson","year":"2017","journal-title":"J. Med. Chem."},{"key":"B23","doi-asserted-by":"publisher","first-page":"18349","DOI":"10.1073\/pnas.0806270105","article-title":"Molecular structural basis for polymorphism in Alzheimer\u2019s \u03b2-amyloid fibrils","volume":"105","author":"Paravastu","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"B24","doi-asserted-by":"publisher","first-page":"4775","DOI":"10.1039\/c9sc00595a","article-title":"Direct conversion of phenols into primary anilines with hydrazine catalyzed by palladium","volume":"10","author":"Qiu","year":"2019","journal-title":"Chem. Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"100150","DOI":"10.1016\/j.tjpad.2025.100150","article-title":"Donanemab: appropriate use recommendations","volume":"12","author":"Rabinovici","year":"2025","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B26","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/978-1-4939-7404-7_10","article-title":"In silico strategies to design small molecules to study beta-amyloid aggregation","volume-title":"Computational Modeling of Drugs Against Alzheimer\u2019s Disease","author":"Rao","year":"2018"},{"key":"B27","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ebiom.2016.03.035","article-title":"The role of amyloid-\u03b2 oligomers in toxicity, propagation, and immunotherapy","volume":"6","author":"Sengupta","year":"2016","journal-title":"EbioMedicine"},{"key":"B29","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1039\/d4md00630e","article-title":"Recent advancements in the therapeutic approaches for Alzheimer\u2019s disease treatment: current and future perspective","volume":"16","author":"Sharma","year":"2025","journal-title":"RSC Med. Chem."},{"key":"B30","doi-asserted-by":"publisher","first-page":"870517","DOI":"10.3389\/fnagi.2022.870517","article-title":"Impact of anti-amyloid-\u03b2 monoclonal antibodies on the pathology and clinical profile of Alzheimer\u2019s disease: a focus on aducanumab and lecanemab","volume":"14","author":"Shi","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3390\/pharmaceutics16050641","article-title":"Simultaneous delivery of curcumin and resveratrol via in situ gelling, raft-forming, gastroretentive formulations","volume":"16","author":"Siripruekpong","year":"2024","journal-title":"Pharmaceutics"},{"key":"B32","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.chembiol.2014.03.004","article-title":"Privileged diazepine compounds and their emergence as bromodomain inhibitors","volume":"21","author":"Smith","year":"2014","journal-title":"Chem. Biol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.3987\/COM-18-14002","article-title":"Multigram-scale and column chromatography-free synthesis of L-azetidine-2-carboxylic acid for the synthesis of nicotianamine and its derivatives","volume":"96","author":"Takaishi","year":"2018","journal-title":"Heterocycles"},{"key":"B34","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1021\/acsptsci.9b00110","article-title":"The discovery of suvorexant: lessons learned that can be applied to other CNS drug development efforts","volume":"3","author":"Uslaner","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.biopsych.2017.08.010","article-title":"Anti-amyloid-\u03b2 monoclonal antibodies for Alzheimer\u2019s disease: pitfalls and promise","volume":"83","author":"van Dyck","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"B36","doi-asserted-by":"publisher","first-page":"7661","DOI":"10.1021\/jo9908501","article-title":"Benzoylation of dianions: preparation of monobenzoylated derivatives of symmetrical secondary diamines","volume":"64","author":"Wang","year":"1999","journal-title":"J. Org. Chem."},{"key":"B37","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.jasms.2005.01.008","article-title":"Elucidation of the presence and location of t-Boc protecting groups in amines and dipeptides using on-column H\/D exchange HPLC\/ESI\/MS","volume":"16","author":"Wolf","year":"2005","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"B38","doi-asserted-by":"publisher","first-page":"9441","DOI":"10.1007\/s11033-023-08889-1","article-title":"BANF1 promotes glutamate-induced apoptosis of HT-22 hippocampal neurons","volume":"50","author":"Yao","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"B39","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/9781118686263.ch2","article-title":"Benzodiazepines","volume-title":"Privileged Structures in Drug Discovery","author":"Yet","year":"2018"},{"key":"B40","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1021\/acsmedchemlett.9b00524","article-title":"Synthesis, cytotoxicity evaluation, and computational insights of novel 1,4-diazepane-based sigma ligands","volume":"11","author":"Zampieri","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"B41","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","article-title":"Recent advances in Alzheimer\u2019s disease: mechanisms, clinical trials and new drug development strategies","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct. Target Ther."}],"container-title":["Frontiers in Chemistry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fchem.2026.1919936\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T22:10:24Z","timestamp":1788214224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fchem.2026.1919936\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":41,"alternative-id":["10.3389\/fchem.2026.1919936"],"URL":"https:\/\/doi.org\/10.3389\/fchem.2026.1919936","relation":{},"ISSN":["2296-2646"],"issn-type":[{"value":"2296-2646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"1919936"}}